Jul. 26 at 1:49 PM
$TRDA I’ve started a position at these levels. Clinical stage biotech with minimal spend, partnership and licensing revenues from a strong rare disease biotech player trading below cash. Another potential headwind that seems to have missed entrada so far is that they’re delivering a gene therapy without the potential/perceived harm of AAV viral vectors (eg
$SRPT). Will buy/build more, if it dips further.
My only critique is that they don’t give guidance on future trial readouts in their corporate pdf so not sure when the catalyst events will take place.